spacer
home > news
INDUSTRY NEWS AND PRESS RELEASES
 

Sense Accelerates Instrument-Free Molecular Diagnostic Test for COVID-19

Pioneering new class of diagnostic product will transform fight against pandemic Scale-up with Phillips-Medisize underway to ensure timely delivery and distribution

April 1, 2020 – Sense Biodetection Limited (Sense) has today announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. More>>

 
phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB
 

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan: More>>

 
phone +49 231 9742 61 00
email contact@protagenproteinservices.com
web www.protagenproteinservices.com
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
 

Qatar Airways Resumes Scheduled Belly-hold Cargo Operations to China in Response to Increased Demand

Qatar Airways becomes the first Middle Eastern carrier to resume belly-hold operations to all of its destinations in China by leveraging the flexibility and reliability of its modern fleet of 250 aircraft. Belly-hold cargo service to Beijing resumed on 30 March, services to Shanghai, Hangzhou and Chengdu will resume on 31 March and Guangzhou and Chongqing will resume on 01 April. More>>

 
phone +974 40222072
email qrmedia@qatarairways.com.qa
web www.qatarairways.com
 

ERT’s At-Home Cardiac Safety Assessment Ensures Clinical Trial Continuity

Company’s expertise, infrastructure and flexibility enable remote ECG assessment for fast-tracked COVID-19 vaccines /therapies and other critical pharmaceuticals

PHILADELPHIA – March 30, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a cardiac safety solution that helps biopharmaceutical researchers continue important clinical trials during current global ‘stay home’ mandates. The solution enables clinician-administered ECG readings ─ using ERT’s provisioned, FDA-cleared devices or other investigative site–owned equipment ─ to evaluate the safety of new vaccines and medical treatments from patients’ homes. More>>

 
phone +1 800 961 5004
email eresearch@ert.com
web www.ert.com
email 1818 Market Street, Suite 1000, Philadelphia, PA 19103
 

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University. More>>

 
phone +44 (0)1782 714181
web https://www.cobrabio.com/
email Cobra Biologics, Stephenson Building Keele Science Park, ST5 5SP, UK
 

Sartorius Supports the Development of the First Vaccine Candidate Against the Novel Coronavirus to Enter Clinical Trials

SHANGHAI, China, March 25, 2020 / B3C newswire / -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. (“CanSinoBIO”) and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences (“Institute of Bioengineering”) in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. CanSinoBIO and the Institute of Bioengineering used Sartorius’ BIOSTAT® STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, thus ensuring the rapid linear amplification of the adenovirus vector (Ad5-nCoV) and ultimately saving time during development. More>>

 
phone +49.551.308.0
email info@sartorius.com
web www.sartorius.com
email Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
 

Our responsibility: employee health and taking care of patients needs

Düsseldorf, March 24, 2020. We as Gerresheimer face up to the special situation in view of the corona virus which is spreading worldwide. We are aware of our role as a key supplier of medicines and supplies for everyday life. More>>

 
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 

Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19

RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic. More>>

 
phone +44 (118) 918-1000
email prahealthsciences@prahs.com
web www.prahs.com
email Green Park, 500 South Oak Way, Reading, RG2 6AD UK
 

CPhI announces new pharma events calendar for 2020

Organizers have acted quickly to secure three new dates for events in Japan, Southeast Asia and North America in response to COVID-19

Amsterdam, 17 March 2020: The CPhI Pharma portfolio confirms new exhibition dates for CPhI Japan, CPhI South East Asia and CPhI North America. Following a detailed review of attendee requirements and event feasibility, the organizers have moved quickly to secure new dates for three editions of the CPhI pharma series. More>>

 
phone +31 (0)20 708 1637
email cphicustomerservice@ubm.com
web www.cphi.com
email Delhi, India
 

Rotech introduce anti-counterfeit UV printing

Coding and marking specialists, Rotech Machines, has introduced invisible ultraviolet (UV) thermal inkjet printing to offer customers enhanced product security and traceability, and to protect against counterfeiting. Invisible to the naked eye, the special UV ink allows customers in all industries to apply discreet or invisible codes that can only be seen under ultraviolet light, making it difficult for fraudsters to replicate, particularly if the codes are placed in different areas by month or by batch. More>>

 
phone +44 (0) 1707 393700
email sales@rotechmachines.com
web https://www.rotechmachines.com/
email Rotech Machines Limited 1 Brownfields Court Welwyn Garden City Hertfordshire AL7 1AJ
 
 
spacer
News and Press Releases

Merck Introduces Parteck® COAT Excipient, a Fast-Dissolving Material for Immediate Release Coating

• Designed to simplify the formulation and coating process for tablets • Optimized particle size leads to fast dissolving and increases coating process efficiency Merck has launched its Parteck® COAT excipient, a new functional material designed for immediate release film coating applications. Parteck® COAT is a particle engineered polyvinyl alcohol (PVA) with a unique particle structure that enables rapid dissolution even at low temperatures leading to an increased process efficiency.
More info >>


White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement